about
MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutationsGenotype phenotype classification of hepatocellular adenomaHNF1α inhibition triggers epithelial-mesenchymal transition in human liver cancer cell lines.Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma.Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumoursHNF1alpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation.Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity In Vitro.Identification of targeted therapy for an aggressive subgroup of muscle-invasive bladder cancers.EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype.Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation.Loss of hepatocyte nuclear factor 1alpha function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis.A Modeling Approach to Explain Mutually Exclusive and Co-Occurring Genetic Alterations in Bladder Tumorigenesis.Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes.Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I.The beta-catenin pathway is activated in focal nodular hyperplasia but not in cirrhotic FNH-like nodules.Childhood leukaemia, polymorphisms of metabolism enzyme genes, and interactions with maternal tobacco, coffee and alcohol consumption during pregnancy.PI3K/AKT pathway activation in bladder carcinogenesis.A phosphokinome-based screen uncovers new drug synergies for cancer driven by liver-specific gain of nononcogenic receptor tyrosine kinases.Note of caution: Contaminations of hepatocellular cell lines.NRF2/KEAP1 and Wnt/β-catenin in the multistep process of liver carcinogenesis in humans and rats.CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.Mutation of TP53 gene is involved in carcinogenesis of hepatic undifferentiated (embryonal) sarcoma of the adult, in contrast with Wnt or telomerase pathways: an immunohistochemical study of three cases with genomic relation in two cases.Germline hepatocyte nuclear factor 1alpha and 1beta mutations in renal cell carcinomas.Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas.Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas.L’Epidermal Growth Factor Receptor (EGFR) est une cible thérapeutique pour un sous-groupe de tumeurs de vessie agressives de phénotype de type basalA Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver ResectionGenotype–phenotype correlation in hepatocellular adenoma: New classification and relationship with HCCClinical, Morphologic, and Molecular Features Defining So-Called Telangiectatic Focal Nodular Hyperplasias of the LiverMutation of TCF1 encoding hepatocyte nuclear factor 1α in gynecological cancerGenotype-phenotype correlation ofCTNNB1mutations reveals different ß-catenin activity associated with liver tumor progressionIdentification de mutations activatrices de gp130 dans la tumorigenèse hépatiqueHepatocellular adenoma subtype classification using molecular markers and immunohistochemistryRecurrent activating mutations of PPARγ associated with luminal bladder tumorsgermline hepatoblastomas demonstrate cisplatin-induced intratumor tertiary lymphoid structuresDual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular CarcinomaInhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by β-Catenin MutationsAnalysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response
P50
Q28277590-ED38BFB9-025C-4E7D-908E-A13072B6A0ECQ28306241-03181C74-66AB-405B-837D-3709F54A8B6CQ34040991-E455C925-8001-4229-9F76-D1275C72656FQ36104399-CBEAB02E-22C5-4271-BBFE-B2B749ED4682Q36998804-727F9787-4867-4654-8A96-282ACD426CBEQ37224637-56E93C7F-ED2A-4D37-BD38-BA52B0A46D60Q38303475-BDDCE7A9-EC5A-40AC-9786-7123E6080E29Q38400913-639B6234-FC79-4CE3-9BBE-65B059EE1005Q38714435-C6648A33-84D8-4407-90A0-1DE7F901F816Q38852418-A1D91646-7E37-4DE9-B294-92A457C31E91Q38976788-96A250D2-5E98-438E-851B-1AE0760F662AQ39113102-93F2D715-A697-4F00-921D-13732EE3EE25Q39757776-13480776-B608-47C4-9EB4-F4DB6322AEBDQ40664601-4D859A52-C2C9-4A6F-8AD3-B56038CDB269Q41747556-9872F9EE-E15B-4E7A-B7E1-7B9BCD428662Q44561295-E30F44C5-3EC8-479B-BE6C-0A40D34C0FD7Q46604709-FCF1C79F-B987-4948-BB3A-EF4ECF59FC48Q46801325-66937AE3-D005-4AD2-BBC1-CB6600133093Q46976450-F8AF13B8-C95F-4531-A4CA-3F620DD8BB08Q48321277-DE84BB88-3308-4344-9A36-81CCA9E6676FQ52827278-1C94C632-ABE3-4FB5-AA38-0A9F1098548DQ53221185-CC5EB22A-24C5-468B-903D-9AF78D066390Q53272755-3AA35B21-F860-4D94-9DAB-25C191AA2BFCQ53360798-5D80D40D-A32F-4B33-A0F9-12B0102DAD6FQ53361716-9B149991-B168-493A-B351-ACD15A47CCA8Q53366237-3B799F46-D45B-472B-B97A-4AE372BD021AQ55457407-41B9D083-51E1-4127-B054-644BCADF279AQ57665209-E79320F5-05B8-4DD2-A53E-8BA3121AEEC6Q57756525-EC1DE3A8-EE9E-4737-A707-39FC6C29F0F9Q57782566-DCC369F5-6880-4AE5-AEA4-E06A7BC17247Q58408401-5C987525-E84F-4568-9715-67CEE8CCA595Q58408508-15F3A952-7271-4BA1-A384-EF19F29D346FQ59938913-2475F6C4-5F4C-43A9-AA78-BC954863AB6FQ59938968-DAE1FD0C-3660-4D1D-B318-CE06FA2B91DFQ59938985-4B19206E-019B-473B-8C62-3EA935944D30Q60907775-AD5F0979-8AC4-48AD-B43E-8E9A24802E8BQ64108385-E9E50621-820A-4BCC-8E5C-352BC17B72D0Q90266644-1DDCE604-50C5-404E-8C07-BB7FE13A1EE0Q91322323-DBFB8F35-7C62-4E37-B990-5F56E3D190BBQ91824075-9DFAC75E-1671-403B-8838-4C34B5686A40
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sandra Rebouissou
@ast
Sandra Rebouissou
@de
Sandra Rebouissou
@en
Sandra Rebouissou
@es
Sandra Rebouissou
@fr
Sandra Rebouissou
@nl
Sandra Rebouissou
@sl
type
label
Sandra Rebouissou
@ast
Sandra Rebouissou
@de
Sandra Rebouissou
@en
Sandra Rebouissou
@es
Sandra Rebouissou
@fr
Sandra Rebouissou
@nl
Sandra Rebouissou
@sl
prefLabel
Sandra Rebouissou
@ast
Sandra Rebouissou
@de
Sandra Rebouissou
@en
Sandra Rebouissou
@es
Sandra Rebouissou
@fr
Sandra Rebouissou
@nl
Sandra Rebouissou
@sl
P106
P21
P31
P496
0000-0003-0188-2271